MYLAXEN (HEXAFLUORENIUM BROMIDE) — FDA Approval NDA009789 (MEDPOINTE PHARM HLC)
MYLAXEN (HEXAFLUORENIUM BROMIDE) — FDA Approval NDA009789 (MEDPOINTE PHARM HLC) is one of 9,000 drug approvals in the DrugApprovals dataset. Key details — Brand name: MYLAXEN; Active ingredients: HEXAFLUORENIUM BROMIDE; Application number: NDA009789.
| Brand name | MYLAXEN |
|---|---|
| Active ingredients | HEXAFLUORENIUM BROMIDE |
| Application number | NDA009789 |
| Sponsor | MEDPOINTE PHARM HLC |
| Dosage form | INJECTABLE |
| Route | INJECTION |
| Marketing status | Discontinued |
| Products in application | 1 |
| Source | openFDA Drugs@FDA |
$1499/mo
Try DrugApprovals →